|
|
 |
|
Viewing report
|
|
|
|
Anxiety Disorders - A Decade of Declining Revenues
Datamonitor, March 2006, Pages: 310
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 200615 -6.0%). This will be primarily due to the launch of numerous generic anxiety drugs from 2006 onwards, which will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs.
Scope of this title:
- Detailed pipeline analysis for key products in development for GAD, SAD, OCD, PTSD, PMDD and panic disorder, plus drug sales forecasts to 2015
- Overview of patient potential segmentation by indication and unmet needs in anxiety disorders across the US, Japan, France, Germany, Italy, Spain & UK
- Benchmarking of key clinical and company attractiveness of late-phase pipeline products
- Detailed clinical trial information and opinions from key thought leaders
Highlights of this title:
To maximize drug revenues as a final step before generic incursion, a number of existing market players are seeking approvals in additional anxiety indications. However, sales of $1.6 billion in 2006 will decline over the long-term to $1.2 billion in 2015.
Manufacturers with existing branded CNS drugs already approved for indications other than anxiety, are also seeking secondary indications in the anxiety market. It is forecast that these drugs will enter the anxiety market from 2007 onwards, and will reach peak anxiety specific revenues of $413m in 2013.
Several novel anxiety drugs will be launched over the forecast period from 2006 onwards, including Predixs PRX-00023 (oral non-azapirone 5-HT1A agonist) in Phase III for GAD, and Schering AG/Berlexs YAZ (low dose drospirenone/ethinyl estradiol) and Wyeths Librel (low dose levonorgestrel/ethinyl estradiol), both in development for PMDD.
Reasons to order your copy:
- Understand unmet needs in the anxiety market based on key opinion leader comments regarding both currently marketed and pipeline products
- Benchmark key late-stage anxiety compounds against current market leaders
- Assess the global sales forecasts of late-stage pipeline drugs for anxiety and examine their clinical and commercial potential
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Anxiety, Phobias & Panic Disorders - 2009 Edition
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity
Strategic Perspectives 2001: Social Anxiety Disorder - The Target Anxiety Market For Leading Players
Thought Leader Insight & Analysis: Anxiety & Depression
Central Nervous System - Anxiety Drug Pipeline Report
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Disease and Therapy Review: Generalized Anxiety Disorder
Central Nervous System Anxiety
Trends in Clinical Trials: Strategies to enhance clinical trial design
|
|
|
|
